HeartSciences Inc. (NASDAQ:HSCS) Sees Significant Growth in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 114,152 shares, an increase of 125.2% from the August 15th total of 50,682 shares. Based on an average daily volume of 167,140 shares, the days-to-cover ratio is currently 0.7 days. Currently, 3.1% of the shares of the stock are sold short.

HeartSciences Stock Down 2.8%

NASDAQ:HSCS traded down $0.10 on Tuesday, hitting $3.44. The stock had a trading volume of 65,649 shares, compared to its average volume of 843,855. The company has a fifty day moving average price of $2.69 and a two-hundred day moving average price of $2.39. HeartSciences has a 1-year low of $1.63 and a 1-year high of $4.35. The stock has a market cap of $13.41 million, a price-to-earnings ratio of -0.87 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings results on Tuesday, September 15th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, analysts anticipate that HeartSciences will post -3.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of HeartSciences to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.